NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Marshall Wace LLP

Marshall Wace LLP raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 161.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288,446 shares of the company's stock after purchasing an additional 178,322 shares during the quarter. Marshall Wace LLP owned about 0.31% of NewAmsterdam Pharma worth $7,413,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $80,000. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at $154,000. Finally, HB Wealth Management LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at $224,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Up 3.3 %

Shares of NASDAQ NAMS opened at $16.79 on Wednesday. The stock has a market capitalization of $1.84 billion, a P/E ratio of -6.46 and a beta of -0.01. The firm's 50-day moving average price is $19.76 and its two-hundred day moving average price is $21.23. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, equities research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on NAMS shares. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC reissued a "buy" rating and issued a $42.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Scotiabank lifted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Finally, UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of "Buy" and an average target price of $43.33.

Insider Activity

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James N. Topper acquired 4,005 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now owns 3,012,434 shares of the company's stock, valued at approximately $63,321,362.68. This trade represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma (NASDAQ:NAMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.